We are a preclinical stage biopharmaceutical company focused on developing novel products for the treatment of neurodegenerative diseases and psychiatric disorders. With our two current and future product candidates, we aim to bring treatments or cures to market at a reasonable cost as quickly as possible. Far too many individuals — patients and caregivers — suffer from the burden […]

We are a blank check company formed under the laws of the State of Delaware on Dec. 30, 2020. We intend to focus our search on companies with significant operating technological advantages that are headquartered in Latin America, as well as businesses located in the United States that cater to the Hispanic community.  (Note: DILA Capital […]

G Squared Ascend II Inc. is a blank check company incorporated as a Cayman Islands exempted company. This is the second blank check company created by Larry Aschebrook, the founder and managing partner of G Squared, a venture fund focused on the tech sector, along with Ward Davis, a principal at G Squared, and Tom […]

We are a biomedical company focused on transforming women’s healthcare by developing novel solutions and next-generation advancements providing significant clinical impact to address severely underserved areas. Our mission is to provide women worldwide with superior minimally-invasive, non-surgical product technologies, accessible in the office, improving patient care and overall health economics. As a woman-founded and led […]

Sprinklr empowers the world’s largest and most loved brands to make their customers happier. We do this with a new category of enterprise software – Unified Customer Experience Management, or Unified-CXM – that enables every customer-facing function across the front office, from Customer Care to Marketing, to collaborate across internal silos, communicate across digital channels, […]

We are an innovative biotechnology company developing transformative allogeneic cell therapies to create products for the treatment of both solid tumor and hematological malignancies with significant unmet medical need. We have created a comprehensive allogeneic cell therapy platform that includes industry-leading induced pluripotent stem cells, or iPSCs, differentiation know-how to generate immune effector cells from […]

iSpecimen’s mission is to accelerate life science research and development, or R&D, with a global marketplace platform that connects researchers to subjects, specimens and associated data. Our vision is to create an “Amazon-like” global Marketplace of patients, biospecimens and data for research to improve the quality of human life.   iSpecimen is a technology-driven company […]

We are a clinical stage biopharmaceutical company developing a new class of antibiotics for infections caused by bacteria listed as priority pathogens by the World Health Organization (“WHO”), the U.S. Centers for Disease Control and Prevention (“CDC”) and the U.S. Food and Drug Administration (“FDA”). Priority pathogens are those which require new antibiotics to address […]

(Note: This biotech company is focused on developing synthetic psychedelic compounds to treat mental health disorders, including treatment-resistant depression, anxiety and substance abuse disorder. Billionaire Peter Thiel invested $12 million in this start-up in November 2020 through Thiel Capital, his venture capital firm, as part of a $125 million private fund-raising round, CNBC reported.)  We […]

(Note: IPOScoop has NO CALL on this deal because it is NOT an IPO. This is a NASDAQ uplisting from the SIX Swiss Exchange Ltd., where the company’s stock trades under the symbol “MOLN.” On June 8, 2021, the last reported sale price was CHF 24.40, equivalent to US$27.14.)    We are a clinical biopharmaceutical […]